新版医保目录落地，淋巴瘤治疗核心创新药已实现全病程医保覆盖

Core Viewpoint - The new national basic medical insurance drug list has officially been implemented, significantly improving the accessibility of innovative therapies for lymphoma treatment, including bispecific antibodies and ADCs [1][4]. Group 1: Impact of New Drug Inclusion - The inclusion of innovative drugs like Gefitinib and Vobasertib in the national medical insurance directory enhances patient accessibility and treatment options for lymphoma [4]. - The new insurance policy allows for comprehensive coverage of core innovative drugs throughout the treatment process for lymphoma, thereby increasing the availability of these therapies [1][4]. Group 2: Patient Needs and Treatment Efficacy - Lymphoma is a common malignant tumor in China, with diffuse large B-cell lymphoma (DLBCL) accounting for approximately 40% of cases, and 30%-40% of patients facing recurrence or refractory conditions [2]. - There is a pressing demand for new drugs among patients with DLBCL, as highlighted in the "2022 White Paper on the Survival Status of DLBCL Patients in China" [3]. Group 3: Historical Context and Improvements - Since the approval of the first targeted CD20 therapy, Rituximab, in 1998, the five-year survival rate for DLBCL patients in China has improved by 10%-15% [5]. - The continuous introduction of innovative drugs into the medical insurance system has led to significant improvements in treatment efficacy and quality of life for lymphoma patients [5]. Group 4: Recommendations for Policy Implementation - Experts emphasize the importance of ensuring that innovative therapies reach patients effectively, advocating for consistent core rules and standards in medical insurance policies across regions [5]. - There is a call for innovative payment methods and a multi-tiered insurance system to facilitate the rapid adoption of new therapies, particularly for difficult-to-treat or relapsed lymphoma patients [5].